Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Rich Hill of Principal Asset Management breaks down where real estate capital is flowing, what’s driving returns, and how 2026 could reshape the market.
From surprise celebrity overload to fewer influencers, USA Today's Ralphie Aversa breaks down the biggest Super Bowl 60 ads and why AI quietly stole the show.
Carl Lukach, CFO of Bob’s Discount Furniture, shares insights on the company’s IPO, growth strategy, and what it means for the future of the furniture market.
